New drug duo aims to shrink throat tumors before standard care
NCT ID NCT07267338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two drugs (pembrolizumab and MRG-003) before standard chemoradiation can shrink tumors in people with advanced nasopharyngeal cancer linked to Epstein-Barr virus. About 35 adults with stage III-IVa disease will receive 3 cycles of the drug combo, then standard treatment, followed by 14 more cycles of pembrolizumab. The goal is to see how many patients have a complete response before starting standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Xiehe Hospital
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy cocktail shows promise against tough throat cancer
- New hope for hard-to-treat nose and throat cancer: targeted drug combo shows promise
- New combo therapy shows promise for advanced nose cancer
- New drug aims to stop aggressive nose cancer from coming back
- New combo therapy targets stubborn nasopharyngeal cancer in phase 3 trial
- New combo therapy aims to outsmart nasopharyngeal cancer